chr2-218661219-A-G
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 11P and 1B. PM2PP3PP5_Very_StrongBP4
The NM_001079866.2(BCS1L):c.232A>G(p.Ser78Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000269 in 1,614,168 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_001079866.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BCS1L | NM_001079866.2 | c.232A>G | p.Ser78Gly | missense_variant | Exon 2 of 8 | ENST00000359273.8 | NP_001073335.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000394 AC: 60AN: 152162Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000465 AC: 117AN: 251484Hom.: 0 AF XY: 0.000471 AC XY: 64AN XY: 135916
GnomAD4 exome AF: 0.000257 AC: 375AN: 1461888Hom.: 0 Cov.: 33 AF XY: 0.000257 AC XY: 187AN XY: 727242
GnomAD4 genome AF: 0.000394 AC: 60AN: 152280Hom.: 0 Cov.: 33 AF XY: 0.000631 AC XY: 47AN XY: 74454
ClinVar
Submissions by phenotype
GRACILE syndrome Pathogenic:7
Variant summary: The BCS1L c.232A>G (p.Ser78Gly) variant involves the alteration of a conserved nucleotide. 4/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 48/122498 control chromosomes at a frequency of 0.0003918, which does not exceed the estimated maximal expected allele frequency of a pathogenic BCS1L variant (0.0004725). Homozygotes of this variant have been reported exclusively in Finnish patients with GRACILE syndrome. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. -
- -
NM_004328.4(BCS1L):c.232A>G(S78G) is classified as pathogenic in the context of BCS1L-related disorders. Sources cited for classification include the following: PMID 12215968 and 21274865. Classification of NM_004328.4(BCS1L):c.232A>G(S78G) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. -
- -
- -
- -
- -
not provided Pathogenic:4
- -
- -
This sequence change replaces serine, which is neutral and polar, with glycine, which is neutral and non-polar, at codon 78 of the BCS1L protein (p.Ser78Gly). This variant is present in population databases (rs28937590, gnomAD 0.4%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individuals with clinical features of BCS1L-related conditions (PMID: 12215968, 12547234, 18386115, 19508421). It is commonly reported in individuals of Finnish ancestry (PMID: 12215968). ClinVar contains an entry for this variant (Variation ID: 6167). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BCS1L protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects BCS1L function (PMID: 12215968, 21274865). For these reasons, this variant has been classified as Pathogenic. -
Functional studies demonstrate that S78G is associated with decreased stability of the BCS1L protein (Visapaa et al., 2002); Transgenic mice with homozygosity for the S78G variant demonstrate decreased BCS1L expression and decreased Rieske iron-sulfur protein incorporation into complex III (Davoudi et al., 2014); This variant is associated with the following publications: (PMID: 21274865, 27997587, 29782205, 28424480, 30530468, 22829922, 18386115, 31980526, 12547234, 27809283, 32637629, 34662929, 24466228, 12215968) -
Pili torti-deafness syndrome Pathogenic:1
- -
Mitochondrial complex III deficiency nuclear type 1 Pathogenic:1
- -
Pili torti-deafness syndrome;C1864002:GRACILE syndrome;C3541471:Mitochondrial complex III deficiency nuclear type 1 Pathogenic:1
- -
BCS1L-related disorder Pathogenic:1
The BCS1L c.232A>G variant is predicted to result in the amino acid substitution p.Ser78Gly. This variant has been reported in the homozygous and compound heterozygous state in individuals with GRACILE syndrome (see, for example, Visapää et al. 2002. PubMed ID: 12215968 and Fellman et al. 2008. PubMed ID: 18386115). Transgenic mice homozygous for the p.Ser78Gly variant resemble the human syndrome with features including hepatopathy with progressive complex III deficiency and short lifespan (see for example Kotarsky et al. 2012. PubMed ID: 22829922). This variant is reported in 0.41% of alleles in individuals of European (Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/) and is interpreted as pathogenic by multiple laboratories in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/6167/). Based on the available evidence, this variant is interpreted as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at